Join the Zepbound group to help and get support from people like you.
Zepbound News
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...
1 in 10 Americans Has Used GLP-1 Drugs For Weight Loss, Survey Says
FRIDAY, Aug. 8, 2025 — More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals. About 12% say they’ve tried GLP-1 drugs, like Ozempic, Weg...
New Weight Loss Pill From Eli Lilly, Orforglipron, Shows Promise in Early Study
FRIDAY, Aug. 8, 2025 — A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an a...
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
THURSDAY, Aug. 7, 2025 – A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have...
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 – Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in...
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 – For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 – For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 – For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1...
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
MONDAY, July 21, 2025 – For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes...
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 – In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals...
Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say
FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to conception, new guidelines say. T...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 – For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD)...
Experts Recommend Healthy Lifestyle Changes Alongside GLP-1 Drug Use
WEDNESDAY, July 16, 2025 — GLP-1 weight-loss drugs like Ozempic and Zepbound are so effective it might seem that a person can lose weight without doing anything at all. But that’s a false notion, exp...
Diet, Exercise Can Help GLP-1 Patients Who Miss Doses
TUESDAY, July 15, 2025 — It can sometimes be tough to fill prescriptions for GLP-1 drugs like Wegovy and Zepbound, given the overwhelming popularity of the breakthrough weight-loss meds. But people w...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome